Reported Earnings • May 27
Full year 2026 earnings released: EPS: ₹3.99 (vs ₹12.70 in FY 2025) Full year 2026 results: EPS: ₹3.99 (down from ₹12.70 in FY 2025). Revenue: ₹1.42b (up 18% from FY 2025). Net income: ₹23.5m (down 69% from FY 2025). Profit margin: 1.7% (down from 6.2% in FY 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 80% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth. Duyuru • May 06
Makers Laboratories Limited to Report Q4, 2026 Results on May 26, 2026 Makers Laboratories Limited announced that they will report Q4, 2026 results on May 26, 2026 New Risk • Apr 01
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). Market cap is less than US$10m (₹922.5m market cap, or US$9.88m). Minor Risk Profit margins are more than 30% lower than last year (0.9% net profit margin). New Risk • Feb 18
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹871.2m market cap, or US$9.61m). Minor Risks Share price has been volatile over the past 3 months (7.6% average weekly change). Profit margins are more than 30% lower than last year (0.9% net profit margin). Reported Earnings • Feb 11
Third quarter 2026 earnings released: EPS: ₹1.59 (vs ₹0.50 loss in 3Q 2025) Third quarter 2026 results: EPS: ₹1.59 (up from ₹0.50 loss in 3Q 2025). Revenue: ₹356.7m (up 29% from 3Q 2025). Net income: ₹9.38m (up ₹12.3m from 3Q 2025). Profit margin: 2.6% (up from net loss in 3Q 2025). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 83% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth. Duyuru • Jan 21
Makers Laboratories Limited to Report Q3, 2026 Results on Feb 10, 2026 Makers Laboratories Limited announced that they will report Q3, 2026 results on Feb 10, 2026 New Risk • Nov 21
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (₹748.2m market cap, or US$8.44m). Minor Risk Share price has been volatile over the past 3 months (6.9% average weekly change). Reported Earnings • Nov 08
Second quarter 2026 earnings released: ₹0.20 loss per share (vs ₹14.94 profit in 2Q 2025) Second quarter 2026 results: ₹0.20 loss per share (down from ₹14.94 profit in 2Q 2025). Revenue: ₹345.3m (up 17% from 2Q 2025). Net loss: ₹1.17m (down 101% from profit in 2Q 2025). Over the last 3 years on average, earnings per share has increased by 78% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Duyuru • Oct 16
Makers Laboratories Limited to Report Q2, 2026 Results on Nov 07, 2025 Makers Laboratories Limited announced that they will report Q2, 2026 results on Nov 07, 2025 Reported Earnings • Aug 09
First quarter 2026 earnings released: EPS: ₹0.74 (vs ₹1.67 loss in 1Q 2025) First quarter 2026 results: EPS: ₹0.74 (up from ₹1.67 loss in 1Q 2025). Revenue: ₹352.7m (up 19% from 1Q 2025). Net income: ₹4.37m (up ₹14.2m from 1Q 2025). Profit margin: 1.2% (up from net loss in 1Q 2025). Over the last 3 years on average, earnings per share has increased by 67% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. New Risk • Jul 29
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ₹867.9m (US$9.99m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.9% average weekly change). Market cap is less than US$10m (₹867.9m market cap, or US$9.99m). Minor Risk Large one-off items impacting financial results. Duyuru • Jul 25
Makers Laboratories Limited to Report Q1, 2026 Results on Aug 08, 2025 Makers Laboratories Limited announced that they will report Q1, 2026 results at 9:15 AM, Indian Standard Time on Aug 08, 2025 Reported Earnings • Jul 10
Full year 2025 earnings released: EPS: ₹12.70 (vs ₹10.62 loss in FY 2024) Full year 2025 results: EPS: ₹12.70 (up from ₹10.62 loss in FY 2024). Revenue: ₹1.21b (up 16% from FY 2024). Net income: ₹74.9m (up ₹137.5m from FY 2024). Profit margin: 6.2% (up from net loss in FY 2024). Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Duyuru • Jul 02
Makers Laboratories Limited, Annual General Meeting, Aug 08, 2025 Makers Laboratories Limited, Annual General Meeting, Aug 08, 2025, at 12:30 Indian Standard Time. New Risk • Jun 23
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ₹850.2m (US$9.80m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.6% average weekly change). Market cap is less than US$10m (₹850.2m market cap, or US$9.80m). Reported Earnings • May 28
Full year 2025 earnings released: EPS: ₹12.70 (vs ₹10.62 loss in FY 2024) Full year 2025 results: EPS: ₹12.70 (up from ₹10.62 loss in FY 2024). Revenue: ₹1.33b (up 27% from FY 2024). Net income: ₹74.9m (up ₹137.5m from FY 2024). Profit margin: 5.6% (up from net loss in FY 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. New Risk • May 19
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 20% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.7% average weekly change). Market cap is less than US$100m (₹814.5m market cap, or US$9.52m). Valuation Update With 7 Day Price Move • May 19
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to ₹165, the stock trades at a trailing P/E ratio of 15.6x. Average trailing P/E is 31x in the Pharmaceuticals industry in India. Total returns to shareholders of 2.1% over the past three years. Duyuru • May 13
Makers Laboratories Limited to Report Q4, 2025 Results on May 26, 2025 Makers Laboratories Limited announced that they will report Q4, 2025 results at 9:15 AM, Indian Standard Time on May 26, 2025 Valuation Update With 7 Day Price Move • Mar 13
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₹126, the stock trades at a trailing P/E ratio of 11.8x. Average trailing P/E is 27x in the Pharmaceuticals industry in India. Total loss to shareholders of 28% over the past three years. New Risk • Feb 13
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ₹856.4m (US$9.85m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 20% per year over the past 5 years. Market cap is less than US$10m (₹856.4m market cap, or US$9.85m). Reported Earnings • Jan 31
Third quarter 2025 earnings released: ₹0.50 loss per share (vs ₹2.61 loss in 3Q 2024) Third quarter 2025 results: ₹0.50 loss per share (improved from ₹2.61 loss in 3Q 2024). Revenue: ₹276.9m (up 4.4% from 3Q 2024). Net loss: ₹2.97m (loss narrowed 81% from 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings. Duyuru • Jan 14
Makers Laboratories Limited to Report Q3, 2025 Results on Jan 29, 2025 Makers Laboratories Limited announced that they will report Q3, 2025 results on Jan 29, 2025 Valuation Update With 7 Day Price Move • Jan 02
Investor sentiment improves as stock rises 27% After last week's 27% share price gain to ₹219, the stock trades at a trailing P/E ratio of 25.8x. Average trailing P/E is 37x in the Pharmaceuticals industry in India. Total returns to shareholders of 17% over the past three years. New Risk • Dec 06
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 36% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.6% average weekly change). Market cap is less than US$100m (₹976.5m market cap, or US$11.5m). Reported Earnings • Oct 30
Second quarter 2025 earnings released: EPS: ₹14.94 (vs ₹2.27 loss in 2Q 2024) Second quarter 2025 results: EPS: ₹14.94 (up from ₹2.27 loss in 2Q 2024). Revenue: ₹400.8m (up 60% from 2Q 2024). Net income: ₹88.2m (up ₹101.6m from 2Q 2024). Profit margin: 22% (up from net loss in 2Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings. Duyuru • Oct 17
Makers Laboratories Limited to Report Q2, 2025 Results on Oct 29, 2024 Makers Laboratories Limited announced that they will report Q2, 2025 results on Oct 29, 2024 New Risk • Oct 08
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ₹806.6m (US$9.61m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.4% average weekly change). Earnings have declined by 54% per year over the past 5 years. Market cap is less than US$10m (₹806.6m market cap, or US$9.61m). New Risk • Sep 25
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.3% average weekly change). Earnings have declined by 54% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₹888.0m market cap, or US$10.6m). New Risk • Aug 05
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 54% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.9% average weekly change). Market cap is less than US$100m (₹989.8m market cap, or US$11.8m). Duyuru • Jul 22
Makers Laboratories Limited to Report Q1, 2025 Results on Aug 06, 2024 Makers Laboratories Limited announced that they will report Q1, 2025 results at 12:15 PM, Indian Standard Time on Aug 06, 2024 Reported Earnings • Jul 13
Full year 2024 earnings released: ₹10.62 loss per share (vs ₹7.90 loss in FY 2023) Full year 2024 results: ₹10.62 loss per share (further deteriorated from ₹7.90 loss in FY 2023). Revenue: ₹1.04b (up 3.1% from FY 2023). Net loss: ₹62.6m (loss widened 32% from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 78 percentage points per year, which is a significant difference in performance. Duyuru • Jul 06
Makers Laboratories Limited, Annual General Meeting, Aug 06, 2024 Makers Laboratories Limited, Annual General Meeting, Aug 06, 2024, at 11:30 Indian Standard Time. Reported Earnings • May 24
Full year 2024 earnings released: ₹10.62 loss per share (vs ₹7.90 loss in FY 2023) Full year 2024 results: ₹10.62 loss per share (further deteriorated from ₹7.90 loss in FY 2023). Revenue: ₹1.06b (up 4.6% from FY 2023). Net loss: ₹62.6m (loss widened 32% from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 75 percentage points per year, which is a significant difference in performance. Duyuru • May 09
Makers Laboratories Limited to Report Q4, 2024 Results on May 23, 2024 Makers Laboratories Limited announced that they will report Q4, 2024 results on May 23, 2024 Duyuru • Feb 15
Makers Laboratories Limited Announces the Resignation of Ms. Surbhi Sharma as Company Secretary / Compliance Officer, Effective March 13, 2024 Makers Laboratories Limited announced the resignation of Ms. Surbhi Sharma as Company Secretary /Compliance Officer. Date of Cessation is March 13, 2024. Reported Earnings • Feb 14
Third quarter 2024 earnings released: ₹2.61 loss per share (vs ₹3.65 loss in 3Q 2023) Third quarter 2024 results: ₹2.61 loss per share (improved from ₹3.65 loss in 3Q 2023). Revenue: ₹268.8m (up 35% from 3Q 2023). Net loss: ₹15.4m (loss narrowed 30% from 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 74 percentage points per year, which is a significant difference in performance. Duyuru • Jan 23
Makers Laboratories Limited to Report Q3, 2024 Results on Feb 13, 2024 Makers Laboratories Limited announced that they will report Q3, 2024 results at 12:15 PM, Indian Standard Time on Feb 13, 2024 Board Change • Dec 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. Additional Non-Executive Independent Director Vishal Jain was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 09
Second quarter 2024 earnings released: ₹2.27 loss per share (vs ₹1.00 loss in 2Q 2023) Second quarter 2024 results: ₹2.27 loss per share (further deteriorated from ₹1.00 loss in 2Q 2023). Revenue: ₹250.6m (down 5.4% from 2Q 2023). Net loss: ₹13.4m (loss widened 108% from 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 83 percentage points per year, which is a significant difference in performance. Duyuru • Oct 20
Makers Laboratories Limited to Report Q2, 2023 Results on Nov 07, 2023 Makers Laboratories Limited announced that they will report Q2, 2023 results on Nov 07, 2023 Reported Earnings • Aug 16
First quarter 2024 earnings released: ₹3.55 loss per share (vs ₹2.82 loss in 1Q 2023) First quarter 2024 results: ₹3.55 loss per share (further deteriorated from ₹2.82 loss in 1Q 2023). Revenue: ₹252.5m (flat on 1Q 2023). Net loss: ₹21.0m (loss widened 30% from 1Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 77 percentage points per year, which is a significant difference in performance. Duyuru • Jul 26
Makers Laboratories Limited to Report Q1, 2024 Results on Aug 14, 2023 Makers Laboratories Limited announced that they will report Q1, 2024 results on Aug 14, 2023 Reported Earnings • Jul 13
Full year 2023 earnings released: ₹7.90 loss per share (vs ₹10.13 profit in FY 2022) Full year 2023 results: ₹7.90 loss per share (down from ₹10.13 profit in FY 2022). Revenue: ₹1.01b (down 21% from FY 2022). Net loss: ₹47.5m (down 195% from profit in FY 2022). Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has increased by 28% per year, which means it is well ahead of earnings. Duyuru • Jul 06
Makers Laboratories Limited, Annual General Meeting, Aug 14, 2023 Makers Laboratories Limited, Annual General Meeting, Aug 14, 2023, at 11:30 Indian Standard Time. Reported Earnings • May 24
Full year 2023 earnings released: ₹7.90 loss per share (vs ₹10.13 profit in FY 2022) Full year 2023 results: ₹7.90 loss per share (down from ₹10.13 profit in FY 2022). Revenue: ₹1.04b (down 19% from FY 2022). Net loss: ₹47.5m (down 195% from profit in FY 2022). Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has increased by 39% per year, which means it is well ahead of earnings. Reported Earnings • Feb 14
Third quarter 2023 earnings released: ₹3.65 loss per share (vs ₹4.13 profit in 3Q 2022) Third quarter 2023 results: ₹3.65 loss per share (down from ₹4.13 profit in 3Q 2022). Revenue: ₹201.4m (down 32% from 3Q 2022). Net loss: ₹22.1m (down 209% from profit in 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 41% per year, which means it is well ahead of earnings. Duyuru • Jan 21
Makers Laboratories Limited to Report Q3, 2023 Results on Feb 13, 2023 Makers Laboratories Limited announced that they will report Q3, 2023 results on Feb 13, 2023 Reported Earnings • Nov 16
Second quarter 2023 earnings released: ₹1.00 loss per share (vs ₹3.54 profit in 2Q 2022) Second quarter 2023 results: ₹1.00 loss per share (down from ₹3.54 profit in 2Q 2022). Revenue: ₹273.8m (down 18% from 2Q 2022). Net loss: ₹6.44m (down 137% from profit in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 52% per year whereas the company’s share price has increased by 56% per year. Duyuru • Nov 01
Makers Laboratories Limited Announces Resignation of Rinku Kholakiya as Company Secretary Makers Laboratories Limited informed that Ms. Rinku Kholakiya, Company Secretary has resigned from the services of the Company with effect from close of business hours on 31st October, 2022 and accordingly, she will cease to be the Company Secretary and Key Managerial Personnel of the company from 1st November, 2022. Duyuru • Oct 20
Makers Laboratories Limited to Report Q2, 2022 Results on Nov 14, 2022 Makers Laboratories Limited announced that they will report Q2, 2022 results on Nov 14, 2022 Reported Earnings • Aug 14
First quarter 2023 earnings released: ₹2.82 loss per share (vs ₹3.69 profit in 1Q 2022) First quarter 2023 results: ₹2.82 loss per share (down from ₹3.69 profit in 1Q 2022). Revenue: ₹264.6m (down 27% from 1Q 2022). Net loss: ₹16.2m (down 189% from profit in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 77% per year but the company’s share price has only increased by 67% per year, which means it is significantly lagging earnings growth. Duyuru • Jul 30
Makers Laboratories Limited to Report Q1, 2023 Results on Aug 12, 2022 Makers Laboratories Limited announced that they will report Q1, 2023 results on Aug 12, 2022 Reported Earnings • Jul 16
Full year 2022 earnings released: EPS: ₹10.12 (vs ₹0.67 loss in FY 2021) Full year 2022 results: EPS: ₹10.12 (up from ₹0.67 loss in FY 2021). Revenue: ₹1.30b (up 89% from FY 2021). Net income: ₹49.8m (up ₹53.1m from FY 2021). Profit margin: 3.8% (up from net loss in FY 2021). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 67% per year but the company’s share price has only increased by 61% per year, which means it is significantly lagging earnings growth. Duyuru • Jul 09
Makers Laboratories Limited, Annual General Meeting, Aug 12, 2022 Makers Laboratories Limited, Annual General Meeting, Aug 12, 2022, at 11:30 Indian Standard Time. Duyuru • May 17
Makers Laboratories Limited to Report Q4, 2022 Results on May 27, 2022 Makers Laboratories Limited announced that they will report Q4, 2022 results on May 27, 2022 Reported Earnings • Feb 10
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Third quarter 2022 results: EPS: ₹4.13 (up from ₹2.24 loss in 3Q 2021). Revenue: ₹308.4m (up 107% from 3Q 2021). Net income: ₹20.3m (up ₹35.4m from 3Q 2021). Profit margin: 6.6% (up from net loss in 3Q 2021). The move to profitability was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has increased by 57% per year, which means it is tracking significantly ahead of earnings growth. Duyuru • Feb 10
Makers Laboratories Limited Appoints Rinku Kholakiya as the Company Secretary, Compliance Officer Makers Laboratories Limited at its the Board meeting February 9, 2022 has appointed Ms. Rinku Kholakiya as the Company Secretary, Compliance Officer and Nodal Officer for IEPF of the Company. Reported Earnings • Nov 12
Second quarter 2022 earnings released: EPS ₹3.54 (vs ₹1.92 in 2Q 2021) The company reported a solid second quarter result with improved earnings and revenues, although profit margins were weaker. Second quarter 2022 results: Revenue: ₹341.4m (up 150% from 2Q 2021). Net income: ₹17.4m (up 85% from 2Q 2021). Profit margin: 5.1% (down from 6.9% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has increased by 46% per year, which means it is well ahead of earnings. Reported Earnings • Jul 18
Full year 2021 earnings released: ₹0.67 loss per share (vs ₹0.25 loss in FY 2020) The company reported a mediocre full year result with increased losses and weaker control over costs, although revenues improved. Full year 2021 results: Revenue: ₹686.4m (up 34% from FY 2020). Net loss: ₹3.29m (loss widened 166% from FY 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 136 percentage points per year, which is a significant difference in performance. Reported Earnings • Jun 14
Full year 2021 earnings released: EPS ₹2.74 (vs ₹0.25 loss in FY 2020) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹686.4m (up 34% from FY 2020). Net income: ₹13.5m (up ₹14.7m from FY 2020). Profit margin: 2.0% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 111 percentage points per year, which is a significant difference in performance. Reported Earnings • Feb 14
Third quarter 2021 earnings released: ₹2.24 loss per share (vs ₹0.31 loss in 3Q 2020) The company reported a mediocre third quarter result with increased losses and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: ₹148.8m (up 32% from 3Q 2020). Net loss: ₹11.0m (loss widened ₹9.45m from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 72% per year but the company’s share price has increased by 52% per year, which means it is well ahead of earnings. Is New 90 Day High Low • Feb 04
New 90-day high: ₹314 The company is up 211% from its price of ₹101 on 06 November 2020. The Indian market is up 23% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 8.0% over the same period. Duyuru • Jan 22
Makers Laboratories Limited to Report Q3, 2021 Results on Feb 10, 2021 Makers Laboratories Limited announced that they will report Q3, 2021 results on Feb 10, 2021 Is New 90 Day High Low • Dec 14
New 90-day high: ₹194 The company is up 137% from its price of ₹81.60 on 15 September 2020. The Indian market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 8.0% over the same period. Valuation Update With 7 Day Price Move • Dec 02
Market bids up stock over the past week After last week's 19% share price gain to ₹166, the stock is trading at a trailing P/E ratio of 71.5x, up from the previous P/E ratio of 60.2x. This compares to an average P/E of 22x in the Pharmaceuticals industry in India. Total returns to shareholders over the past three years are 75%. Valuation Update With 7 Day Price Move • Nov 23
Market bids up stock over the past week After last week's 16% share price gain to ₹144, the stock is trading at a trailing P/E ratio of 62.3x, up from the previous P/E ratio of 53.7x. This compares to an average P/E of 22x in the Pharmaceuticals industry in India. Total returns to shareholders over the past three years are 64%. Valuation Update With 7 Day Price Move • Nov 12
Market bids up stock over the past week After last week's 19% share price gain to ₹118, the stock is trading at a trailing P/E ratio of 50.9x, up from the previous P/E ratio of 42.7x. This compares to an average P/E of 22x in the Pharmaceuticals industry in India. Total returns to shareholders over the past three years are 24%. Is New 90 Day High Low • Nov 11
New 90-day high: ₹112 The company is up 47% from its price of ₹76.30 on 13 August 2020. The Indian market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 4.0% over the same period. Reported Earnings • Nov 06
Second quarter 2021 earnings released: EPS ₹1.92 The company reported a decent second quarter result with improved earnings and profit margins, although revenues were weaker. Second quarter 2021 results: Revenue: ₹137.8m (down 21% from 2Q 2020). Net income: ₹9.42m (up 197% from 2Q 2020). Profit margin: 6.8% (up from 1.8% in 2Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 60% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings. Duyuru • Oct 28
Makers Laboratories Limited to Report Q2, 2021 Results on Nov 04, 2020 Makers Laboratories Limited announced that they will report Q2, 2021 results on Nov 04, 2020 Is New 90 Day High Low • Oct 22
New 90-day high: ₹108 The company is up 70% from its price of ₹63.65 on 24 July 2020. The Indian market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 13% over the same period. Is New 90 Day High Low • Oct 05
New 90-day high: ₹96.60 The company is up 95% from its price of ₹49.65 on 07 July 2020. The Indian market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 18% over the same period. Duyuru • Sep 30
Makers Laboratories Limited (BSE:506919) made an offer to acquire 26% stake in Resonance Specialties Limited (BSE:524218) for approximately 170 million. Makers Laboratories Limited (BSE:506919) made an offer to acquire 26% stake in Resonance Specialties Limited (BSE:524218) for approximately 170 million on September 29, 2020. Under the terms of the transaction, Makers Laboratories made an offer to acquire up to 3,001,440 shares from shareholders of Resonance Specialties at INR 55.5 per share. The Offer Price is payable in cash. In related transactions, Makers Laboratories agreed to acquire 45.48% stake in Resonance Specialties from Ushma Investments Pvt Ltd and Vista Finance & Leasing Private Ltd. through block deal and Kaygee Investments, a person acting in concert agreed to acquire 8.76% stake from Vista Finance & Leasing Private Ltd. through off-market purchase. Prior to these transactions, Makers Laboratories do not hold any stake in Resonance Specialties. On September 29, 2020, the Board of Directors of Makers Laboratories approved this transaction. Amol Kshirsagar and Satish Kumar of Arihant Capital Markets Limited (BSE:511605) acted as financial advisor to the Makers Laboratories. Duyuru • Sep 26
Makers Laboratories Limited Announces Resignation of P. M. Kathariya as Independent Director and Member of the Committees of the Board of the Company Makers Laboratories Limited announced that Mr. P. M. Kathariya, Independent Director has informed the Company of his inability to continue as a member of the Board of Directors and his intention to resign as the Independent Director/Member of the Committees of the Board of the Company due to his professional pre-occupation as well as personal reasons vide his letter dated September 22, 2020. Duyuru • Aug 13
Makers Laboratories Limited Omits Dividend for the Financial Year Ended on March 31, 2020 Makers Laboratories Limited announced that the Board of Directors do not recommend dividend for the financial year ended on March 31, 2020. Duyuru • Aug 10
Makers Laboratories Limited to Report Q1, 2021 Results on Aug 12, 2020 Makers Laboratories Limited announced that they will report Q1, 2021 results on Aug 12, 2020 
